Phase 1 Study of IMC-CS4, a Monoclonal Antibody Targeted to the CSF-1 Receptor (CSF-1R), in Subjects With Advanced Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy is Available
A study for patients with advanced solid tumors using study drug IMC-CS4
Sponsor: Eli Lilly and Company
Enrolling: Male and Female Patients
IRB Number: AAAQ8124
U.S. Govt. ID: NCT01346358
Contact: Richard Carvajal: 646-317-6041 / carvajalr@columbia.edu
Additional Study Information: The purpose of this study is to see if IMC-CS4 (LY3022855) is safe to give to patients. We want to see how you feel when you are receiving treatment, what effects, good and/or bad, the study drug has on you and your tumor and which may be the best dose.
This study is closed
Investigator
Richard Carvajal, MD
Do You Qualify?
Have you been diagnosed with advanced solid tumors? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder


CAPTCHA
Image CAPTCHA
Enter the characters shown in the image.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Cancel
For more information, please contact:
Richard Carvajal
carvajalr@columbia.edu
646-317-6041
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE